CompanyGraph
Shanghai Haohai Biological Technology Co., Ltd.
688366 · SSE · China
3healthcare.comFinancials as of FY2025
What stands out
- Pays more per share than it earned over the last twelve months
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionPrice-to-book is 1.22×, lower than 95% of its Biotechnology peers (median 4.62×)
- FinancialsAltman Z-Score 5.18: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Pays more per share than it earned over the last twelve months
Dividends view
Yield
1.66%Above 5Y avg (1.23%)
Annual Rate
CNY 0.50Paid semi-annual
Payout Ratio
151.5%High
Payback Period
35.7 yr
Last Ex-Dividend
Sep 18, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.74BCNY1.01B · vs all stocks (USD)
Trailing P/E
43.74xvs Biotechnology peers
Revenue (TTM)
2.32BCNY346.46M · vs all stocks (USD)
Profit Margin
6.57%vs Biotechnology peers
Beta
0.4710xvs all stocks
52-Week Change
-42.09%vs all stocks
Forward Annual Dividend Yield
1.66%vs all stocks
Market Capitalization
6.74BCNY1.01B · vs all stocks (USD)
Enterprise Value
4.68BCNY699.30M · vs all stocks (USD)
Trailing P/E
43.74xvs Biotechnology peers
Forward P/E
11.64xvs Biotechnology peers
Price to Sales (TTM)
2.79xvs Biotechnology peers
Price to Book (MRQ)
1.22xvs Biotechnology peers
Enterprise to Revenue
2.02xvs Biotechnology peers
Enterprise to EBITDA
15.10xvs Biotechnology peers
Profit Margin
6.57%vs Biotechnology peers
Operating Margin
2.49%vs Biotechnology peers
Return on Assets (TTM)
1.13%vs Biotechnology peers
Return on Equity (TTM)
2.07%vs Biotechnology peers
Revenue (TTM)
2.32BCNY346.46M · vs all stocks (USD)
Revenue per Share (TTM)
10.06CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-11.40%vs Biotechnology peers
Gross Profit (TTM)
1.55BCNY230.78M · vs all stocks (USD)
EBITDA (TTM)
433.94MCNY64.77M · vs all stocks (USD)
Net Income (TTM)
152.57MCNY22.77M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-67.60%vs Biotechnology peers
Operating Cash Flow (TTM)
316.00MCNY47.17M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-104.10MCNY-15.54M · vs all stocks (USD)
Forward Annual Dividend Rate
0.5000CNYUpdated Sep 22, 2026Forward Annual Dividend Yield
1.66%vs all stocks
Trailing Annual Dividend Rate
0.8500CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
2.82%vs all stocks
5-Year Average Dividend Yield
1.23%vs all stocks
Payout Ratio
151.52%vs Biotechnology peers
Minority Interest (Equity)
182.72MCNYFY2025 · Dec 31, 2025Revenue
2.45BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
734.73MCNYFY2025 · Dec 31, 2025Gross Profit
1.71BCNYFY2025 · Dec 31, 2025Operating Income
317.13MCNY47.34M · vs all stocks (USD)
Pre-tax Income
239.25MCNYFY2025 · Dec 31, 2025Income Tax Expense
30.92MCNYFY2025 · Dec 31, 2025Net Income
208.32MCNYFY2025 · Dec 31, 2025EBIT
258.12MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
433.94MCNYFY2025 · Dec 31, 2025Research & Development
197.78MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.25BCNYFY2025 · Dec 31, 2025Non-operating Interest Income
76.88MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
18.88MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.08CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.08CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
231.80MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
231.80MSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
42.69MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
110.82MCNYFY2025 · Dec 31, 2025Free Cash Flow
-67.47MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.23BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
239.25MCNYFY2025 · Dec 31, 2025Stock-based Compensation
0.00CNYFY2025 · Dec 31, 2025Other Non-cash Items
-66.23MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-12.17MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-50.02MCNYFY2025 · Dec 31, 2025Capital Expenditures
-178.28MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.75MCNYFY2025 · Dec 31, 2025Net Acquisitions
80.58MCNYFY2025 · Dec 31, 2025Purchase of Investments
-32.26MCNYFY2025 · Dec 31, 2025Sale of Investments
330.42MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
200.46MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
235.89MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-287.09MCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-148.62MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-228.74MCNYFY2025 · Dec 31, 2025Other Financing Charges
-57.42MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-485.97MCNYFY2025 · Dec 31, 2025Shares Outstanding
224.98MSharesUpdated Sep 22, 2026Float Shares
83.40MSharesUpdated Sep 22, 2026% Held by Insiders
73.56%vs all stocks
% Held by Institutions
0.57%vs all stocks
Total Cash (MRQ)
2.40BCNY358.54M · vs all stocks (USD)
Total Cash per Share (MRQ)
10.69CNYUpdated Sep 22, 2026Total Debt (MRQ)
443.22MCNY66.16M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0812xvs Biotechnology peers
Current Ratio (MRQ)
3.49xvs Biotechnology peers
Book Value per Share (MRQ)
23.59CNYUpdated Sep 22, 2026Total Assets
6.72BCNY1.00B · vs all stocks (USD)
Total Current Assets
3.46BCNYFY2025 · Dec 31, 2025Total Liabilities
1.12BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.26BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
200.89MCNYFY2025 · Dec 31, 2025Total Current Liabilities
914.67MCNYFY2025 · Dec 31, 2025Cash
1.23BCNYFY2025 · Dec 31, 2025Cash Equivalents
1.22BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.45BCNYFY2025 · Dec 31, 2025Other Short-term Investments
76.11MCNYFY2025 · Dec 31, 2025Accounts Receivable
271.00MCNYFY2025 · Dec 31, 2025Inventory
522.88MCNYFY2025 · Dec 31, 2025Accounts Payable
68.14MCNYFY2025 · Dec 31, 2025Short-term Debt
334.59MCNYFY2025 · Dec 31, 2025Long-term Debt
63.91MCNYFY2025 · Dec 31, 2025Common Stock (Book)
230.56MCNYFY2025 · Dec 31, 2025Retained Earnings
2.90BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.60BCNY836.58M · vs all stocks (USD)
Treasury Stock
310.86MCNYFY2025 · Dec 31, 202552-Week Low
27.60CNYUpdated Sep 22, 202652-Week High
52.88CNYUpdated Sep 22, 202652-Week Change
-42.09%vs all stocks
Beta
0.4710xvs all stocks
50-Day MA
31.01CNYUpdated Sep 22, 2026200-Day MA
37.84CNYUpdated Sep 22, 2026Avg 10-Day Volume
317.49KSharesUpdated Sep 22, 2026Avg 30-Day Volume
646.48KSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.6600CNYUpdated Sep 22, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Retained Earnings Heavy With Elevated Payout
Profits kept in the business fund much of what it owns, and it now pays out most of what it earns.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 1.22×, lower than 95% of its Biotechnology peers (median 4.62×)Notable
Price-to-book: 1.22Industry median: 4.62Industry P5: 1.32Peers compared: 193
Structural Tensions
Pays more per share than it earned over the last twelve monthsSignificant
Payout Ratio: 1.52Dividend per Share: 0.85Earnings per Share: 0.66
Financial Health
Altman Z-Score 5.18: safe zoneNotable
Altman Z-Score: 5.18
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Blue Jet Healthcare Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
0009K0
Tier 1ProductionApproval-Gated PipelineRuleRisk
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sunflower Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sino Medical Sciences Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Wanbang Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pacira BioSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Kanghua Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Dezhan Health Care Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shantou Institute of Ultrasonic Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Beijing Strong Biotechnologies, Inc.
2 interpretationsRetained Earnings Heavy With Elevated PayoutHigh Retained Earnings With Profitability And Equity
Assure Tech Hangzhou Co., Ltd.
2 interpretationsRetained Earnings Heavy With Elevated PayoutHigh Retained Earnings With Profitability And Equity
Tracsis Plc
2 interpretationsRetained Earnings Heavy With Elevated PayoutHigh Retained Earnings With Profitability And Equity